Clinical trials: Brain Stroke
Subarachnoid Hemorrhage, Ruptured Intracranial Aneurysm
Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms
This is a randomized, double-blind, placebo-controlled, single-dose study investigating the safety and efficacy of NA-1 in patients with subarachnoid hemorrhage (SAH) undergoing endovascular repair of ruptured intracranial…
- Trial name
- ENACT-2 (NCT02056574)
- Testing
- NA-1
- Where
- 12 sites in United States, Canada
- Sponsor
- NoNO Inc.
Stroke, Stroke, Acute
Evaluation of the Use of the Atalante System in Patients Presenting a Non-traumatic Hemiplegia in Acute-subacute Phase (15 Days to 6 Months).
The SPIRIT study is interventional, national, prospective, open, multicentric each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients presenting…
- Conditions
- Stroke, Stroke, Acute, Stroke, Subacute, Robotics
- Trial name
- SPIRIT (NCT04187209)
- Testing
- Use of the Atalante exoskeleton
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Wandercraft
Stroke
Pilot Investigation of Stem Cells in Stroke
The study is designed to test the safety of a manufactured neural stem cell line (CTX cells) delivered by injection into the damaged brains of male patients 60 years of age or over who remain moderately to severely disabled 6…
- Trial name
- PISCES (NCT01151124)
- Testing
- CTX0E03 neural stem cells
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- ReNeuron Limited
Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)
This is a national, multicenter, cross-sectional, observational study within a convenience sample of Internal Medicine departments from 100 hospitals in Spain which agree to participate in the study.
- Trial name
- NCT02447341
- Where
- Spain
- Volunteers
- 987 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Acquired Brain Injury (Including Stroke)
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting
The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting.
- Trial name
- NCT07050875
- Testing
- ABLE Exoskeleton
- Where
- 3 sites in Spain
- Volunteers
- 14 people
- Sponsor
- ABLE Human Motion S.L.
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke
To evaluate the safety and efficacy of using Microport CardioAdvance Left Atrium Appendage Closure for preventing stroke in Non-valvular atrial fibrillation (NVAF) patients who have contraindications for long-term…
- Trial name
- SAFE-PROTECT (NCT04479722)
- Testing
- Left atrial appendage closure procedure
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Ischemic Stroke
Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.
To explore the rule of absorption, distribution, metabolism and elimination after intravenous administration of Ginkgolides Meglumine Injection healthy subjects.
- Trial name
- NCT02046031
- Testing
- Ginkgolides Meglumine Injection
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT01978730
- Testing
- high dose group of SaiLuoTong capsule, low dose group of SaiLuoTong, the control group
- Where
- 16 sites in China
- Volunteers
- 372 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Subacute Stroke, Upper Extremity Function
AI-based Customized tDCS for Finger Motor Recovery After Subacute Stroke
The goal of this clinical study is to evaluate whether AI-based customized transcranial direct current stimulation (tDCS) using MR images is more effective than sham stimulation in improving finger motor function in patients with…
- Trial name
- NCT07491029
- Testing
- AI-based Customized transcranial Direct Current Stimulation
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- NEUROPHET
Cerebral Stroke
CERENOVUS Neurothrombectomy Devices Registry
A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed…
- Trial name
- EXCELLENT (NCT03685578)
- Testing
- EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter, CEREGLIDE 71 Intermediate Catheter
- Where
- 40 sites in United States, Belgium and 5 more
- Volunteers
- 2,000 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
The KHENERFIN study aims to determine whether the study medicine, sonlicromanol, is able to reduce symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able to improve physical abilities of…
- Conditions
- Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Trial name
- KH176-301 (NCT06451757)
- Testing
- Sonlicromanol
- Where
- 10 sites in United States, Denmark and 5 more
- Volunteers
- 220 people
- Sponsor
- Khondrion BV
Hemiparesis of the Upper Limb Following Stroke
MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke
The purpose of this study is to examine the efficacy of MyndMove therapy in the early sub-acute, late sub-acute and chronic post-stroke patients.
- Trial name
- NCT02266836
- Testing
- MyndMove
- Where
- 6 sites in Canada
- Volunteers
- 50 people
- Sponsor
- MyndTec Inc.
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
- Trial name
- NCT06380699
- Testing
- QHRD106 Injection, Human Urinary Kallidinogenase
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Atherosclerotic Disease, Carotid
SmartRisk Stroke Prediction by MRI of Carotid Disease
Atherosclerotic plaque at the carotid artery bifurcation is a major source of stroke. The purpose of this investigation is to determine the ability of the SmartRisk software module to predict stroke or stroke-related events due…
- Trial name
- SmartRisk (NCT00860184)
- Where
- 15 sites in United States
- Volunteers
- 300 people
- Sponsor
- VPDiagnostics
Stroke, PFO - Patent Foramen Ovale
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
The purpose of this post-marketing surveillance is to evaluate the effectiveness and safety of GORE® CARDIOFORM Septal Occluder under the post-marketing setting in Japan.
- Conditions
- Stroke, PFO - Patent Foramen Ovale, Cryptogenic Stroke, TIA
- Trial name
- GSO-PFO PMS (NCT05529901)
- Testing
- GORE® CARDIOFORM Septal Occluder
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- W.L.Gore & Associates
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.